Benzinga | Dec 17, 2021 06:07AM EST

Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $215

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $220 to $215.